Experience with COVID-19 infection and immunization in a group of adult patients with cystic fibrosis
Orv Hetil. 2024 Mar 3;165(9):332-337. doi: 10.1556/650.2024.32994. Print 2024 Mar 3.ABSTRACTBevezetés: Habár a nem transzplantált, cystás fibrosisban szenvedő betegek többségében enyhe lefolyást mutat a COVID–19-fertőzés, a betegek kis hányadában súlyos lefolyású kórforma alakul ki. Célkitűzés: A célok között szerepelt azoknak a rizikófaktoroknak az azonosítása, amelyek megnövelik a koronavírussal fertőzött cystás fibrosisos betegek hospitalizációs igényét, emellett a betegek átoltottságát és a fertőzésben alkalmazott kezeléseket is vizsgálni kívántuk. Módszer: Az Országos K...
Source: Orvosi Hetilap - March 3, 2024 Category: General Medicine Authors: Zolt án Örlős Zsuzsanna Mikl ós Ildik ó Horváth Source Type: research

Experience with COVID-19 infection and immunization in a group of adult patients with cystic fibrosis
Orv Hetil. 2024 Mar 3;165(9):332-337. doi: 10.1556/650.2024.32994. Print 2024 Mar 3.ABSTRACTBevezetés: Habár a nem transzplantált, cystás fibrosisban szenvedő betegek többségében enyhe lefolyást mutat a COVID–19-fertőzés, a betegek kis hányadában súlyos lefolyású kórforma alakul ki. Célkitűzés: A célok között szerepelt azoknak a rizikófaktoroknak az azonosítása, amelyek megnövelik a koronavírussal fertőzött cystás fibrosisos betegek hospitalizációs igényét, emellett a betegek átoltottságát és a fertőzésben alkalmazott kezeléseket is vizsgálni kívántuk. Módszer: Az Országos K...
Source: Orvosi Hetilap - March 3, 2024 Category: General Medicine Authors: Zolt án Örlős Zsuzsanna Mikl ós Ildik ó Horváth Source Type: research

Experience with COVID-19 infection and immunization in a group of adult patients with cystic fibrosis
Orv Hetil. 2024 Mar 3;165(9):332-337. doi: 10.1556/650.2024.32994. Print 2024 Mar 3.ABSTRACTBevezetés: Habár a nem transzplantált, cystás fibrosisban szenvedő betegek többségében enyhe lefolyást mutat a COVID–19-fertőzés, a betegek kis hányadában súlyos lefolyású kórforma alakul ki. Célkitűzés: A célok között szerepelt azoknak a rizikófaktoroknak az azonosítása, amelyek megnövelik a koronavírussal fertőzött cystás fibrosisos betegek hospitalizációs igényét, emellett a betegek átoltottságát és a fertőzésben alkalmazott kezeléseket is vizsgálni kívántuk. Módszer: Az Országos K...
Source: Orvosi Hetilap - March 3, 2024 Category: General Medicine Authors: Zolt án Örlős Zsuzsanna Mikl ós Ildik ó Horváth Source Type: research

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy
Nutr Clin Pract. 2024 Apr;39 Suppl 1:S57-S77. doi: 10.1002/ncp.11122.ABSTRACTCystic fibrosis (CF) is a progressive, genetic, multi-organ disease affecting the respiratory, digestive, endocrine, and reproductive systems. CF can affect any aspect of the gastrointestinal (GI) tract, including the esophagus, stomach, small intestine, colon, pancreas, liver, and gall bladder. GI pathophysiology associated with CF results from CF membrane conductance regulator (CFTR) dysfunction. The majority of people with CF (pwCF) experience exocrine pancreatic insufficiency resulting in malabsorption of nutrients and malnutrition. Additional...
Source: Nutrition in Clinical Practice - March 2, 2024 Category: Nutrition Authors: Catherine M McDonald Elizabeth K Reid John F Pohl Tatiana K Yuzyuk Laura M Padula Kay Vavrina Kimberly Altman Source Type: research

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy
Nutr Clin Pract. 2024 Apr;39 Suppl 1:S57-S77. doi: 10.1002/ncp.11122.ABSTRACTCystic fibrosis (CF) is a progressive, genetic, multi-organ disease affecting the respiratory, digestive, endocrine, and reproductive systems. CF can affect any aspect of the gastrointestinal (GI) tract, including the esophagus, stomach, small intestine, colon, pancreas, liver, and gall bladder. GI pathophysiology associated with CF results from CF membrane conductance regulator (CFTR) dysfunction. The majority of people with CF (pwCF) experience exocrine pancreatic insufficiency resulting in malabsorption of nutrients and malnutrition. Additional...
Source: Nutrition in Clinical Practice - March 2, 2024 Category: Nutrition Authors: Catherine M McDonald Elizabeth K Reid John F Pohl Tatiana K Yuzyuk Laura M Padula Kay Vavrina Kimberly Altman Source Type: research

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy
Nutr Clin Pract. 2024 Apr;39 Suppl 1:S57-S77. doi: 10.1002/ncp.11122.ABSTRACTCystic fibrosis (CF) is a progressive, genetic, multi-organ disease affecting the respiratory, digestive, endocrine, and reproductive systems. CF can affect any aspect of the gastrointestinal (GI) tract, including the esophagus, stomach, small intestine, colon, pancreas, liver, and gall bladder. GI pathophysiology associated with CF results from CF membrane conductance regulator (CFTR) dysfunction. The majority of people with CF (pwCF) experience exocrine pancreatic insufficiency resulting in malabsorption of nutrients and malnutrition. Additional...
Source: Nutrition in Clinical Practice - March 2, 2024 Category: Nutrition Authors: Catherine M McDonald Elizabeth K Reid John F Pohl Tatiana K Yuzyuk Laura M Padula Kay Vavrina Kimberly Altman Source Type: research

Galectin-3 levels in children with cystic fibrosis
Conclusion: The study shows that serum Galectin-3 levels increased in clinically stable CF patients, and serum Galectin-3 response may depend on age, gender, and BMI. The sputum Galectin-3 was found to be negatively correlated with patients ’ lung functions.What is known:• Galectin-3 is a key regulator of chronic inflammation in the lung, liver, kidney, and tumor microenvironment.What is new:• Children with cystic fibrosis (CF) have higher serum Galectin-3 concentrations than healthy children.• Serum Galectin-3 expression influenced by age, BMI, and gender in children with CF. (Source: European Journal of Pediatrics)
Source: European Journal of Pediatrics - March 2, 2024 Category: Pediatrics Source Type: research

A skin-interfaced, miniaturized platform for triggered induction, capture and colorimetric multicomponent analysis of microliter volumes of sweat
Biosens Bioelectron. 2024 Feb 23;253:116166. doi: 10.1016/j.bios.2024.116166. Online ahead of print.ABSTRACTEccrine sweat can serve as a source of biomarkers for assessing physiological health and nutritional balance, for tracking loss of essential species from the body and for evaluating exposure to hazardous substances. The growing interest in this relatively underexplored class of biofluid arises in part from its non-invasive ability for capture and analysis. The simplest devices, and the only ones that are commercially available, exploit soft microfluidic constructs and colorimetric assays with purely passive modes of ...
Source: Biosensors and Bioelectronics - March 1, 2024 Category: Biotechnology Authors: Joohee Kim Seyong Oh Da Som Yang Larissa Rugg Radhika Mathur Sung Soo Kwak Seonggwang Yoo Shupeng Li Evangelos E Kanatzidis Geumbee Lee Hong-Joon Yoon Yonggang Huang Roozbeh Ghaffari Susanna A McColley John A Rogers Source Type: research

A skin-interfaced, miniaturized platform for triggered induction, capture and colorimetric multicomponent analysis of microliter volumes of sweat
Biosens Bioelectron. 2024 Feb 23;253:116166. doi: 10.1016/j.bios.2024.116166. Online ahead of print.ABSTRACTEccrine sweat can serve as a source of biomarkers for assessing physiological health and nutritional balance, for tracking loss of essential species from the body and for evaluating exposure to hazardous substances. The growing interest in this relatively underexplored class of biofluid arises in part from its non-invasive ability for capture and analysis. The simplest devices, and the only ones that are commercially available, exploit soft microfluidic constructs and colorimetric assays with purely passive modes of ...
Source: Biosensors and Bioelectronics - March 1, 2024 Category: Biotechnology Authors: Joohee Kim Seyong Oh Da Som Yang Larissa Rugg Radhika Mathur Sung Soo Kwak Seonggwang Yoo Shupeng Li Evangelos E Kanatzidis Geumbee Lee Hong-Joon Yoon Yonggang Huang Roozbeh Ghaffari Susanna A McColley John A Rogers Source Type: research

Magnetic Resonance Imaging of Pulmonary and Paranasal Sinus Abnormalities in Children with Primary Ciliary Dyskinesia Compared to Children with Cystic Fibrosis
Annals of the American Thoracic Society,Volume 21, Issue 3, Page 438-448, March 2024. (Source: Annals of the American Thoracic Society)
Source: Annals of the American Thoracic Society - March 1, 2024 Category: Respiratory Medicine Authors: Lena Wucherpfennig Felix Wuennemann Monika Eichinger Niclas Schmitt Angelika Seitz Ingo Baumann Jobst F. Roehmel Mirjam Stahl Susanne H ämmerling Jaehi Chung Jens-Peter Schenk Abdulsattar Alrajab Hans-Ulrich Kauczor Marcus A. Mall Mark O. Wielp ütz Olaf Source Type: research

Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease
Annals of the American Thoracic Society,Volume 21, Issue 3, Page 411-420, March 2024. (Source: Annals of the American Thoracic Society)
Source: Annals of the American Thoracic Society - March 1, 2024 Category: Respiratory Medicine Authors: Thomas Radtke Don S. Urquhart Julia Braun Peter J. Barry Ian Waller Nicole Petch Meir Mei-Zahav Mordechai R. Kramer Thong Hua-Huy Anh Tuan Dinh-Xuan J. Alastair Innes Sara McArthur Aleksandar Sovtic Bojana Gojsina Samuel Verges Tanguy de Maat Lisa Morriso Source Type: research

Cardiopulmonary Exercise Testing for Prognostication in Advanced Cystic Fibrosis Lung Disease and Beyond
Annals of the American Thoracic Society,Volume 21, Issue 3, Page 380-381, March 2024. (Source: Annals of the American Thoracic Society)
Source: Annals of the American Thoracic Society - March 1, 2024 Category: Respiratory Medicine Authors: Tijana Milinic Kathleen J. Ramos Source Type: research

Year in review 2023 – Back to the future
This review synthesizes articles published in 2023, focusing on the impact of elexacaftor-tezacaftor-ivacaftor (ETI) in cystic fibrosis (CF) care. Real-world data highlights sustained benefits of ETI across age groups, while challenges like neuropsychological side effects persist. Beyond CFTR modulators, research explores telemedicine and novel therapies. Prioritizing equitable access and addressing unmet needs remain crucial for comprehensive CF management. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - March 1, 2024 Category: Respiratory Medicine Authors: Luca Cristiani, Fl ávia Fonseca Fernandes Source Type: research

Chronicity Counts: The Impact of < em > P. aeruginosa < /em > , < em > S. aureus < /em > , and Co-Infection in Cystic Fibrosis
Am J Respir Crit Care Med. 2024 Feb 29. doi: 10.1164/rccm.202312-2326LE. Online ahead of print.NO ABSTRACTPMID:38422389 | DOI:10.1164/rccm.202312-2326LE (Source: American Journal of Respiratory and Critical Care Medicine)
Source: American Journal of Respiratory and Critical Care Medicine - February 29, 2024 Category: Respiratory Medicine Authors: Micaela Mossop Jonathan Ish-Horowicz Dominic Hughes Rebecca Dobra Alessandra G Cunanan Mark Rosenthal Siobh án B Carr Newara Ramadan Laura M Nolan Jane C Davies Source Type: research